1672.HK实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (3 May 2024 @ 16:08):

Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China and internationally...

Stats
今日成交量	1.17M
平均成交量	885 204
市值	1.43B
EPS	HKD0 ( 2023-08-22 )
下一个收益日期	( HKD0 ) 2024-05-23
Last Dividend	HKD0 ( N/A )
Next Dividend	HKD0 ( N/A )
P/E	-9.47
ATR14	HKD0.00600 (0.42%)

音量相关性

長: -0.07 (neutral)

短: -0.74 (moderate negative)

Signal:(58.577) Neutral

Ascletis Pharma Inc 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Ascletis Pharma Inc 相关性 - 货币/商品

-0.45
( neutral )

-0.53
( weak negative )

0.00
( neutral )

-0.47
( neutral )

0.57
( weak )

0.17
( neutral )

Ascletis Pharma Inc 财务报表

Annual	2023
营收:	HKD56.60M
毛利润:	HKD25.99M (45.92 %)
EPS:	HKD-0.130

FY	2023
营收:	HKD56.60M
毛利润:	HKD25.99M (45.92 %)
EPS:	HKD-0.130

FY	2022
营收:	HKD54.09M
毛利润:	HKD-24.69M (-45.65 %)
EPS:	HKD-0.340

FY	2021
营收:	HKD76.88M
毛利润:	HKD39.17M (50.96 %)
EPS:	HKD-0.191

Financial Reports:

No articles found.

Ascletis Pharma Inc

Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China and internationally. The company offers Ritonavir oral tablet, a pharmacokinetic booster of various oral antiviral drugs targeting viral proteases and a component of the approved oral antiviral drug Paxlovid; ASCLEVIR and GANOVO for the treatment of Hepatitis C virus. It is also developing ASC22 for treating chronic hepatitis B (CHB) and human immunodeficiency virus functional cure; ASC42 for chronic hepatitis B functional cure; ASC10 and ASC11 to treat COVID-19; ASC40, ASC41, ASC42, ASC43F FDC, ASC44F FDC, and ASC45F FDC for non-alcoholic steatohepatitis; and ASC42 for the treatment of primary biliary cholangitis. In addition, the company is developing ASC40 to treat recurrent glioblastoma, drug resistant breast cancer, and KRAS mutant non-small cell lung cancer; ASC61 and ASC63 for advanced solid tumors; ASC60 to treat solid tumors; and ASC40 for the treatment of acne, Ascletis Pharma Inc. was founded in 2013 and is headquartered in Hangzhou, the People's Republic of China.